N
Nectero Medical
Nectero Medical is working on an innovative treatment to stabilize growth and prevent rupture of mid-sized abdominal aortic aneurysms
About Nectero Medical
Nectero Medical is a pioneering company in the medical technology sector, focusing on the development of innovative treatments for abdominal aortic aneurysms (AAA). The company targets patients with mid-sized AAAs, providing a novel solution that stabilizes aneurysm growth and prevents rupture. Operating within the healthcare market, Nectero Medical's core product, the EAST Stabilizer, offers a safer and quicker alternative to traditional treatments such as Endovascular Aneurysm Repair (EVAR) and open surgical repair. The EAST Stabilizer is a localized drug delivery system that strengthens the vessel wall by cross-linking within the tissue, thereby reducing the risk of rupture. This single treatment procedure can be performed in under one hour, significantly shorter than the 3 to 4 hours required for EVAR and even longer for open surgical repair. Nectero Medical's business model revolves around providing this advanced medical solution to healthcare providers and patients, generating revenue through the sale and distribution of the EAST Stabilizer system. The company serves a niche market of patients who are under annual or semi-annual imaging protocols to monitor aneurysm growth until it reaches a critical size for treatment. By offering a less invasive and safer alternative, Nectero Medical aims to improve patient outcomes and reduce the need for more complex surgical interventions. Keywords: abdominal aortic aneurysm, medical technology, EAST Stabilizer, localized drug delivery, vessel wall strengthening, healthcare, safer treatment, quicker procedure, aneurysm stabilization, innovative solution.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Tempe, United States
- Employees
- 34
- Open positions
- None listed
- Dealroom signal
- 45.1/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Drug Development, Cardiology and cardiovascular, Spinout, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Nectero Medical.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES DOther financing | Apr 2024 | $96M | $384M | Boston Scientific · Cadence Healthcare Ventures · Norwest Venture Partners · Aphelion Capital | ↗ |
| SERIES COther financing | Sep 2021 | $20M | $78M | Boston Scientific · PneumRx | — |
Growth signals
Latest recorded traffic for Nectero Medical is 1.3K monthly website visits, up 18.2% over the last three months. Nectero Medical's team declined 5.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later6 investors entered at this stage
- PNPneumRx
Boston Scientific
Norwest Venture Partners
Cadence Healthcare Ventures- ACAphelion Capital
BioStar Capital
Other known investors1 additional known investor
Clemson University, South Carolina
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Nectero Medical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nectero Medical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.






